Table 4.

Target therapies (part II).

Electrolyte disorder	Drug	Incidence (%) Type of study	Mechanism(s)
Hypokalemia Hyperkalemia	Cetuximab, Panitumumab Lumretuzumab, Pertuzumab (combined with paclitaxel) Bevacizumab Temsirolimus, Everolimus Tremelimumab, Blinatumomab, Volasertib, Eribulin Mesilate DRUG-INDUCING-TLS (MoAbs, TKI, PI, CAR-T) IMMUNOMODULATORS (Thalidomide, Lenaldomide)	6 (<3 mmol/L) (D) (97) 8 (all grade) (D) (97) 57 (all grade) (D); 40 (<3.0 mmol/L) (D) (98) n.a. n.a.	Renal potassium wasting due to hypomagnesemia (97, 99) Drug-induced secretory diarrhea (98) Proximal tubular damage (100) Acquired FS (101) Unclear; Possible drug-induced diarrhea (102–105) TLS (34, 101)
Hypomagnesemia	Cetuximab, Panitumumab Zalutumumab, Nimotuzumab Cetuximab (combined with irinotecan) Lumretuzumab,Pertuzumab (combined with paclitaxel)	2-6 (<0.9 mg/dl) (D) (99, 106) 5.9 (<0.9 mg/dl) [D] (107) 34; 3% (<0.9 mg/dl) (D) (98, 99, 106)	Renal magnesium wasting due to TRPM6/EGF/EGFR blockade (99, 108) Drug-induced secretory diarrhea (98)

Incidence and type of study column: the letter after the percentage indicates the type of evidence available: A isolated case; B case series; C pharmacovigilance notifications or registry; D observational study, clinical trial, metanalysis of clinical trials. n.a. not available. References in bracket square. CAR-T, Chimeric Antigen Receptor-T; FS= Fanconi Syndrome; MoAbs, Monoclonal Antibodies; PI, Proteasome Inhibitors; TKI, Tyrosine Kinase Inhibitors; TLS, Tumor Lysis Syndrome; TRPM6, Transient Receptor Potential Cation Channel, subfamily M, member 6/EGF, Epidermal Growth Factor.